Radium: all 52 studies that test it

Page 1 of 1. Open to participants first (1), then studies with results posted, then the rest; newest registration first within each.

• Radium-223 for High-Volume Metastatic Hormone Sensitive Prostate CancerNot yet recruitingNCT07717099Phase 2
• RAdium-223 and SABR Versus SABR for Oligometastatic Prostate CancersCompletedNCT04037358Phase 2Results posted
• Study to Test the Safety and How Radium-223 Dichloride an Alpha Particle-emitting Radioactive Agent Works in Combination With Pembrolizumab an Immune Checkpoint Inhibitor in Patients With Stage IV Non-small Cell Lung Cancer With Bone MetastasesTerminatedNCT03996473Phase 1Results posted
• Radium-223 and Radiotherapy in Hormone-Naïve Men With Oligometastatic Prostate Cancer to BoneCompletedNCT03304418Phase 2Results posted
• Trial of Rad-223 Activity in Asymptomatic Patients With mCRPC While on Abiraterone or Enzalutamide Besides AR-V7 StatusCompletedNCT03002220Phase 2Results posted
• Study Testing Radium-223 Dichloride in Relapsed Multiple MyelomaTerminatedNCT02928029Phase 1/2Results posted
• Prostate Cancer Intensive, Non-Cross Reactive Therapy (PRINT) for Castration Resistant Prostate Cancer (CRPC)CompletedNCT02903160Phase 2Results posted
• Study of Sipuleucel-T W/ or W/O Radium-223 in Men With Asymptomatic or Minimally Symptomatic Bone-MCRPCCompletedNCT02463799Phase 2Results posted
• Trial of Ra-223 Dichloride in Combination With Hormonal Therapy and Denosumab in the Treatment of Patients With Hormone-Positive Bone-Dominant Metastatic Breast CancerCompletedNCT02366130Phase 2Results posted
• A Biomarker Study of Standard-of-care Radium-223 Chloride for Metastatic Castration-resistant Prostate CancerCompletedNCT02346526Phase 2Results posted
• BrUOG L301 With Non-Small Cell Lung Cancer and Bone MetastasesCompletedNCT02283749Phase 2Results posted
• Non-Randomized Trial Assessing Pain Efficacy With Radium-223 in Symptomatic Metastatic Castration-Resistant Prostate CancerCompletedNCT02278055Phase 2Results posted
• Study of Radium-223 Dichloride Versus Placebo and Hormonal Treatment as Background Therapy in Subjects With Bone Predominant HER2 (Human Epidermal Growth Factor Receptor 2) Negative Hormone Receptor Positive Metastatic Breast CancerTerminatedNCT02258464Phase 2Results posted
• Study of Radium-223 Dichloride in Combination With Exemestane and Everolimus Versus Placebo in Combination With Exemestane and Everolimus in Subjects With Bone Predominant HER2 Negative Hormone Receptor Positive Metastatic Breast CancerCompletedNCT02258451Phase 2Results posted
• Radium Ra 223 With Enzalutamide Compared to Enzalutamide Alone in Men With Metastatic Castration Refractory Prostate CancerCompletedNCT02199197Phase 2Results posted
• Radium 223 in Castrate Resistant Prostate Cancer Bone MetastasesCompletedNCT02135484Not applicableResults posted
• Open Label Phase Two Trial of Radium Ra 223 Dichloride With Concurrent Administration of Abiraterone Acetate Plus Prednisone in Symptomatic Castration-Resistant (Hormone-Refractory) Prostate Cancer Subjects With Bone MetastasisCompletedNCT02097303Phase 2Results posted
• Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild SymptomsCompletedNCT02043678Phase 3Results posted
• Standard Dose Versus High Dose and Versus Extended Standard Dose Radium-223 Dichloride in Castration-resistant Prostate Cancer Metastatic to the BoneCompletedNCT02023697Phase 2Results posted
• Re-treatment Safety of Radium-223 Dichloride in Castration-resistant Prostate Cancer With Bone MetastasesCompletedNCT01934790Phase 1/2Results posted
• Phase I Dose Escalation of Monthly Intravenous Ra-223 Dichloride in OsteosarcomaCompletedNCT01833520Phase 1/2Results posted
• A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal MetastasesCompletedNCT00699751Phase 3Results posted
• Efficacy of Ra-223 in PSMA PET Optimally Selected PatientsActive, not recruitingNCT05924672Phase 2
• Darolutamide With Radium-223 or Placebo and the Effect on Radiological Progression-Free Survival for Patients With mCSPCWithdrawnNCT05771896Phase 3
• Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men with Metastatic Castration-Resistant Prostate CancerActive, not recruitingNCT05383079Phase 1/2
• RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)Active, not recruitingNCT04597125Phase 4
• A Study to Assess How Radium-223 Distributes in the Body of Patients With Prostate Cancer Which Spread to the BonesCompletedNCT04521361Phase 1
• Radium-223 in Biochemically Recurrent Prostate CancerActive, not recruitingNCT04206319Phase 2
• Study of Nivolumab in Combination w Radium-223 in Men w Metastatic Castration Resistant Prostate CancerActive, not recruitingNCT04109729Phase 1
• A Study to Test Radium-223 With Docetaxel in Patients With Prostate CancerActive, not recruitingNCT03574571Phase 3
• Radium-223 Combined With Dexamethasone as First-line Therapy in Patients With M+CRPCActive, not recruitingNCT03432949Phase 4
• Sequencing of Radium-223 and Docetaxel in Symptomatic Bone-only Metastatic Castration-resistant Prostate CancerActive, not recruitingNCT03230734Phase 2
• Radium-223 and Atezolizumab in Patients With Urothelial Carcinoma With Bone Metastases Who Have Had Disease Progression After Platinum-Based ChemotherapyTerminatedNCT03208712Early Phase 1
• Metabolic Change in Prostate Cancer Bone Metastases on 68Ga-HBED-CC-PSMA PET/CT Following Radium-223 TherapyCompletedNCT03062254Phase 2
• Dose-finding, Safety and Efficacy Study of Radium-223 Dichloride (XOFIGO) in RCC Patients With Bone Metastases. (EIFFEL)Status unknownNCT02880943Phase 1/2
• Safety and Tolerability of Atezolizumab (ATZ) in Combination With Radium-223 Dichloride (R-223-D) in Metastatic Castrate-Resistant Prostate Cancer (CRPC) Progressed Following Treatment With an Androgen Pathway InhibitorCompletedNCT02814669Phase 1
• Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple MyelomaWithdrawnNCT02605356Phase 1/2
• Treatment of Advanced Castration Resistant Prostate Carcinoma With Limited Bone Metastases (α-RT)Status unknownNCT02484339Phase 2
• Phase Ib Study of Radium Ra 223 Dichloride in Combination With Paclitaxel in Cancer Subjects With Bone LesionsCompletedNCT02442063Phase 1
• Radium-223 in Combination With EnzalutamideCompletedNCT02225704Phase 2
• Phase III Radium 223 mCRPC-PEACE IIIActive, not recruitingNCT02194842Phase 3
• Japanese BAY88-8223 Monotherapy Phase II StudyCompletedNCT01929655Phase 2
• Radium-223 Dichloride Asian Population Study in the Treatment of CRPC Patients With Bone MetastasisCompletedNCT01810770Phase 3
• Quadruple Therapy Versus Dual Therapy as Rescue Regimens for Helicobacter Pylori InfectionCompletedNCT01805934Phase 2
• Radium(223) Dichloride (Alpharadin) in Castration-Resistant (Hormone-Refractory) Prostate Cancer Patients With Bone MetastasesCompletedNCT01618370Phase 3
• Safety, Biodistribution, Radiation Dosimetry and Pharmacokinetics Study of BAY88-8223 in Japanese PatientsCompletedNCT01565746Phase 1
• BAY88-8223, Alpharadin, Breast Cancer Patients With Bone Dominant DiseaseCompletedNCT01070485Phase 2
• Alpharadin™ (Radium-223 Chloride) Safety and Dosimetry With HRPC That Has Metastasized to the SkeletonCompletedNCT00748046Phase 1
• PK in Pts With HRPC & Skeletal MetastesCompletedNCT00667537Phase 1
• BAY88-8223, Does Response Study in HRPC PatientsCompletedNCT00667199Phase 2
• A Placebo-controlled Phase II Study of Bone-targeted Radium-223 in Symptomatic Hormone-refractory Prostate CancerCompletedNCT00459654Phase 2
• BAY88-8223, Dose Finding Study in Patients With HRPCCompletedNCT00337155Phase 2

← Radium overview